Independent international pharmaceutical company Servier and a leader in the manufacture printed on the bio-printer living tissue company Poiti joined forces to print the liver tissue of a person which contains the line of liver cells and immunocompetent human cells.
What is the progress of the study of the liver and print on 4-d bio-printer
Up to this point in their study, researchers used animal models as well as models based on human cell cultures. However, they do not allow with sufficient accuracy to assess the hepatotoxic potential of drugs. Through innovative 4D models, scientists hope to improve the efficiency of drug discovery and liver already at the stage of preclinical studies.
CEO and Director of business development Puati, Bruno Brisson, has high hopes for further cooperation with the company Servier:
We are very excited to announce the beginning of a partnership with Servier. Specialists in pre-clinical research this company have the highest qualification in the study of toxicity in vitro using a variety of tools. We are very proud to be partnered with Servier. Our planned development will allow to achieve more accurate result in accordance with the requirements of the application of new tools, including the control of morphogenesis and standardization.
According to Nancy Claude, Director of the division of preclinical research company Servier, such cooperation is already at the stage of clinical trials will help to reduce the number of undesirable side effects against hepatic function, which may have drugs. The project will help to obtain new data enabling to promptly detect any adverse effects of developed drugs.
See also:to REPLACE DISEASED ORGANS PRINTED will START in 5 YEARS
4D bioprinting in the pharmaceutical industry
Helen ERTS, head of in vitro platform Biologie Servier, the companybelieves that the new method allows inclusion of different types of single cells in extracellular matrix, will give the opportunity to recreate microdan for in vitro testing of the inflammatory response and the phenomenon of remodeling tissues.
Dr. Fabien Guillemot, CEO and chief scientific officer of the company Puati, believes that the cooperation will help to implement the 4D bioprinting in the pharmaceutical industry.
This partnership is long term and aimed at creating liver tissue using the technology of bioprinting, this is an important step towards the implementation of the method of 4D-bioprinting in the pharmaceutical industry. Research partnership with Servier entered into after our interaction with KULв the field of bioprinting cartilage, to the strategy Poiti aimed at the widespread use of this technique in dermatology.